AstraZeneca Shows That With Immune Cancer Drugs, No One Knows What’s Next

Shares in AstraZeneca are up 9% to $33.82 after the London-based drug giant announced that its cancer drug Imfinzi worked in a clinical trial to slow the progression of lung tumors in patients whose cancer was not treatable with surgery, capping off a week that’s driven home a clear message about a class of cancer drugs Wall Street analysts think could be generating $30 billion in annual sales over the next decade. The message?

You puny humans have no idea what is going to happen next.

Read Full Article Here >>